Showing results (291-300 of 308) with videos related to

Sort By:
Pageof 31
Journal of Crohn'S & Colitis|September 7, 2025
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel DiseaseUma Mahadevan, Cynthia H Seow, Edward L Barnes, et al.
The American Journal of Gastroenterology|June 15, 2016
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY ConsortiumParambir S Dulai, Siddharth Singh, Xiaoqian Jiang, et al.
The American Journal of Gastroenterology|April 4, 2018
Ileocecal Anastomosis Type Significantly Influences Long-Term Functional Status, Quality of Life, and Healthcare Utilization in Postoperative Crohn's Disease Patients Independent of Inflammation RecurrenceMahesh Gajendran, Anthony J Bauer, Bettina M Buchholz, et al.
Pharmaceutics|April 26, 2025
The Clinical Utility of Precision-Guided Dosing for Adalimumab Therapy Optimization in Inflammatory Bowel Disease: A Clinical Experience ProgramStephen B Hanauer, Esther A Torres, Patricia Aragon-Han, et al.
Alimentary Pharmacology & Therapeutics|December 24, 2019
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's diseaseParambir S Dulai, Aurelien Amiot, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.
Crohn'S & Colitis 360|February 13, 2023
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center ExperienceGuilherme Piovezani Ramos, Badr Al-Bawardy, Manuel Bonfim Braga Neto, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
BMJ Open Gastroenterology|March 31, 2025
Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trialSiddharth Singh, Jasmine D Nguyen, David I Fudman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 10, 2019
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative ColitisDavid M Faleck, Adam Winters, Shreya Chablaney, et al.
Pageof 31